Lipoic acid

DB00166

small molecule approved investigational nutraceutical

Deskripsi

A vitamin-like antioxidant.

Struktur Molekul 2D

Berat 206.326
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

142 Data
Insulin human The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin human.
Insulin lispro The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin lispro.
Insulin glargine The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin glargine.
Insulin pork The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin pork.
Troglitazone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Troglitazone.
Glimepiride The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Glimepiride.
Sulfisoxazole The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Sulfisoxazole.
Disopyramide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Disopyramide.
Acarbose The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Acarbose.
Sulfadiazine The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Sulfadiazine.
Rosiglitazone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Rosiglitazone.
Acetohexamide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Acetohexamide.
Quinine The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Quinine.
Miglitol The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Miglitol.
Chlorpropamide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Chlorpropamide.
Pentamidine The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Pentamidine.
Mifepristone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Mifepristone.
Tolazamide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Tolazamide.
Repaglinide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Repaglinide.
Phenformin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Phenformin.
Sulfamethoxazole The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Sulfamethoxazole.
Glyburide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Glyburide.
Glipizide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Glipizide.
Gliclazide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Gliclazide.
Tolbutamide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Tolbutamide.
Bromocriptine The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Bromocriptine.
Gliquidone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Gliquidone.
Mitiglinide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Mitiglinide.
Sitagliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Sitagliptin.
Sunitinib The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Sunitinib.
Exenatide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Exenatide.
Mecasermin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Mecasermin.
Pramlintide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Pramlintide.
Glisoxepide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Glisoxepide.
Insulin aspart The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin aspart.
Insulin detemir The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin detemir.
Insulin glulisine The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin glulisine.
Glymidine The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Glymidine.
AICA ribonucleotide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with AICA ribonucleotide.
Buformin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Buformin.
Vildagliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Vildagliptin.
Voglibose The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Voglibose.
NN344 The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with NN344.
AMG-222 The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with AMG-222.
Bisegliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Bisegliptin.
Alogliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Alogliptin.
Dapagliflozin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Dapagliflozin.
Saxagliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Saxagliptin.
Liraglutide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Liraglutide.
Gosogliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Gosogliptin.
Linagliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Linagliptin.
Canagliflozin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Canagliflozin.
Glibornuride The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Glibornuride.
Benfluorex The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Benfluorex.
Empagliflozin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Empagliflozin.
Albiglutide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Albiglutide.
Dulaglutide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Dulaglutide.
Lobeglitazone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Lobeglitazone.
Netoglitazone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Netoglitazone.
Rivoglitazone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Rivoglitazone.
Ciglitazone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Ciglitazone.
Lixisenatide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Lixisenatide.
Insulin beef The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin beef.
Insulin degludec The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin degludec.
Insulin peglispro The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin tregopil.
Ipragliflozin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Ipragliflozin.
Dutogliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Dutogliptin.
Allicin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Allicin.
Tofogliflozin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Tofogliflozin.
Ertugliflozin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Ertugliflozin.
2,4-thiazolidinedione The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with 2,4-thiazolidinedione.
Teneligliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Teneligliptin.
Omarigliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Omarigliptin.
Carmegliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Carmegliptin.
Gemigliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Gemigliptin.
Anagliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Anagliptin.
Evogliptin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Evogliptin.
Sotagliflozin The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Sotagliflozin.
Balaglitazone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Balaglitazone.
Remogliflozin etabonate The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Remogliflozin etabonate.
Carbutamide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Carbutamide.
Guar gum The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Guar gum.
Metahexamide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Metahexamide.
Semaglutide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Semaglutide.
Taspoglutide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Taspoglutide.
Englitazone The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Englitazone.
Tirzepatide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Tirzepatide.
Gastric inhibitory polypeptide The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Gastric inhibitory polypeptide.
Cisplatin The risk or severity of cytotoxicity can be decreased when Lipoic acid is combined with Cisplatin.
Iron Dextran Iron Dextran can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prussian blue Prussian blue can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron sucrose Iron sucrose can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric pyrophosphate Ferric pyrophosphate can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric ammonium citrate Ferric ammonium citrate can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxsil Ferumoxsil can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferumoxides Ferumoxides can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric sulfate Ferric sulfate can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferrous bisglycinate Ferrous bisglycinate can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gleptoferron Gleptoferron can cause a decrease in the absorption of Lipoic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.

Target Protein

Lipoyl amidotransferase LIPT1, mitochondrial LIPT1
Sodium-dependent multivitamin transporter SLC5A6
Lipoyl synthase, mitochondrial LIAS

Referensi & Sumber

Synthesis reference: Joachim Paust, Peter Eckes, Wolfgang Siegel, Friedhelm Balkenhohl, Walter Dobler, Michael Hullmann, "Preparation of R/S-.gamma.-lipoic acid or R/S-.alpha.-lipoic acid." U.S. Patent US5489694, issued July, 1961.
Artikel (PubMed)
  • PMID: 10966480
    Perham RN: Swinging arms and swinging domains in multifunctional enzymes: catalytic machines for multistep reactions. Annu Rev Biochem. 2000;69:961-1004.
  • PMID: 14854913
    REED LJ, DeBUSK BG, GUNSALUS IC, HORNBERGER CS Jr: Crystalline alpha-lipoic acid; a catalytic agent associated with pyruvate dehydrogenase. Science. 1951 Jul 27;114(2952):93-4.
  • PMID: 26245877
    Arnold J, Morgan B: Management of Lead Encephalopathy with DMSA After Exposure to Lead-Contaminated Moonshine. J Med Toxicol. 2015 Dec;11(4):464-7. doi: 10.1007/s13181-015-0493-9.
  • PMID: 36548551
    Patwa J, Thakur A, Flora SJS: Alpha Lipoic Acid and Monoisoamyl-DMSA Combined Treatment Ameliorates Copper-Induced Neurobehavioral Deficits, Oxidative Stress, and Inflammation. Toxics. 2022 Nov 24;10(12):718. doi: 10.3390/toxics10120718.

Contoh Produk & Brand

Produk: 23 • International brands: 1
Produk
  • Corvita
    Tablet, coated • - • Oral • US
  • Corvite
    Tablet, coated • - • Oral • US
  • Corvite Free
    Tablet, coated • - • Oral • US
  • Dayavite
    Tablet, coated • - • Oral • US
  • Dyzbac
    Tablet • - • Oral • US
  • Dyzbac
    Tablet • - • Oral • US
  • Fibrik
    Capsule • - • Oral • US
  • Folic-K
    Capsule • - • Oral • US
Menampilkan 8 dari 23 produk.
International Brands
  • Biletan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul